Health Technology Assessment (HTA) has been defined by the International Network of Agencies for HTA (INAHTA) as "a multidisciplinary field of policy analysis, studying the medical, economic, social, and ethical implications of development, diffusion and use of health technologies (e.g., drugs, devices, surgical procedures, prevention techniques)".
In conducting HTA, the discipline of decision sciences has become increasingly relevant.
Decision Sciences (DS) is the application of explicit and quantitative methods to analyze decisions under conditions of uncertainty (e.g., meta-analysis, decision-analytic modeling, cost-effectiveness analysis).
In recent years, HTA and DS have become very important to health care policymakers.
In order to keep pace with these developments, the UMIT - HTADS Program was designed to provide excellent quality education and comprehensive training in the key issues of HTA and DS for anyone involved in the health sector.
Prof. Uwe Siebert, MD, MPH, MSc, ScD
Professor of Public Health (UMIT)
Adjunct Professor of Health Policy and Management (Harvard University)
Director, Institute of Public Health, Medical Decision Making and Health Technology Assessment
Chair, Department of Public Health and Health Technology Assessment
UMIT - University for Health Sciences, Medical Informatics and Technology
|Doctoral Program Health Technology Assessment|
|6-Day Certified Course
Winter School in Clinical Epidemiology
|30 Nov. - 5 Dec. 2015||Course brochure
|4-Day Certified Course
Introduction to Health Technology Assessment
|22 - 25 April 2015||Course brochure|
|3-Day Certified Course
Modeling Approaches for HTA: A Practical Hands-on Workshop
Comments of participants of our previous courses:
'The 4-day course helped me to better understand the framework for HTA, and put the bits and pieces together. The course was dynamic, and assuming that people have some basic previous knowledge, it provides with the maximum effect. We were wondering that the participants were still smiling after 12 hours of work - quite uncommon for any training course.'
Mikk Jurisson, MD
Merck Sharp & Dome, Managing Director Baltics
'Meine Intention, diesen Kurs zu besuchen, war HTAs besser verstehen und bewerten zu lernen. Diese Erwartung wurde vom Kurs voll erfüllt! In diesem perfekt organisierten Lehrgang wurde die komplexe Thematik von HTA und Decision-Analytic Modeling von Herrn Univ.-Prof. Uwe Siebert in einer sehr übersichtlich strukturierten Weise aufgearbeitet und es wurde ein fundierter Einblick in die Methodik von HTA und Decision-Analytic Modeling gegeben.'
Dr. Siegfried Preindl
Tiroler Gebietskrankenkasse, Medical Director of the Public Health Insurance